Compare ECX & RZLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ECX | RZLT |
|---|---|---|
| Founded | 2017 | 2010 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 412.6M | 420.8M |
| IPO Year | 2022 | 2011 |
| Metric | ECX | RZLT |
|---|---|---|
| Price | $1.04 | $4.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $9.67 |
| AVG Volume (30 Days) | 655.5K | ★ 1.4M |
| Earning Date | 05-12-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.32 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $819.14 | N/A |
| Revenue Next Year | $32.36 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.88 | $1.07 |
| 52 Week High | $2.70 | $11.46 |
| Indicator | ECX | RZLT |
|---|---|---|
| Relative Strength Index (RSI) | 49.51 | 51.35 |
| Support Level | $0.99 | $4.48 |
| Resistance Level | $1.13 | $5.36 |
| Average True Range (ATR) | 0.05 | 0.27 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 62.96 | 34.31 |
ECARX Holdings Inc is engaged in the sales of system-on-chip core modules, automotive computing platform products, and software stacks as well as the provision of research and development services in the Peoples Republic of China. The companies core products include infotainment head units, digital cockpits, vehicle chip-set solutions, a core operating system, and an integrated software stack. Beyond this, ECARX is developing a full-stack automotive computing platform. It is engaged in automotive intelligence and networking.
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.